Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.33 |
| ▸ | REN known ✓ | P00797 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 14/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4130340 | 1.00 | NAMPT (0.36) | NAMPTSLC6A4P2RX7RENCYP2C9 | |
| Fumaric Acid SCHEMBL4131498 | 0.93 | NAMPT (0.35) | NAMPTSLC6A4P2RX7CYP2C9PTGS2 | |
| Fumaric Acid SCHEMBL4131511 | 0.93 | NAMPT (0.35) | NAMPTSLC6A4P2RX7CYP2C9PTGS2 | |
| Fumaric Acid SCHEMBL3705828 | 0.92 | P2RX7 (0.36) | NAMPTSLC6A4P2RX7CYP2C9PTGDR2 | |
| Fumaric Acid SCHEMBL3705824 | 0.92 | P2RX7 (0.36) | NAMPTSLC6A4P2RX7CYP2C9PTGDR2 | |
| Fumaric Acid SCHEMBL3702866 | 0.91 | NR2F2 (0.36) | NAMPTP2RX7CYP2C9PTGS2 | |
| Fumaric Acid SCHEMBL3702871 | 0.91 | NR2F2 (0.36) | NAMPTP2RX7CYP2C9PTGS2 | |
| Fumaric Acid SCHEMBL4126491 | 0.89 | NAMPT (0.41) | NAMPTRENPTGDR2 | |
| Fumaric Acid SCHEMBL4126500 | 0.89 | NAMPT (0.41) | NAMPTRENPTGDR2 | |
| Fumaric Acid SCHEMBL3704583 | 0.89 | NAMPT (0.36) | NAMPTSLC6A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC6A4 3372/4885REN 1158/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.